百利天恒涨2.05%,成交额2.21亿元,主力资金净流入233.65万元

Core Viewpoint - Baili Tianheng's stock has shown significant volatility, with a year-to-date increase of 76.17%, but recent declines in the short term raise concerns about its performance and investor sentiment [1][2]. Group 1: Stock Performance - On December 26, Baili Tianheng's stock price increased by 2.05%, reaching 337.78 CNY per share, with a trading volume of 2.21 billion CNY and a turnover rate of 0.65% [1]. - The company's market capitalization stands at 139.46 billion CNY [1]. - Year-to-date, the stock has risen by 76.17%, but it has experienced a decline of 4.75% over the last five trading days, 10.99% over the last 20 days, and 10.76% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Baili Tianheng reported a revenue of 2.066 billion CNY, a year-on-year decrease of 63.52% [2]. - The company recorded a net profit attributable to shareholders of -495 million CNY, reflecting a year-on-year decrease of 112.16% [2]. Group 3: Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 25.08% to 5,979, while the average number of circulating shares per person decreased by 20.05% to 17,208 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by major funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited [3].

BIOKIN PHARMACEUTICAL-百利天恒涨2.05%,成交额2.21亿元,主力资金净流入233.65万元 - Reportify